[
  {
    "ts": null,
    "headline": "Myrtelle Inc. Launches Manufacturing of First-in-Class Gene Therapy for Canavan Disease in Strategic Alliance with Charles River and Viralgen Vector Core",
    "summary": "Myrtelle Inc. announced the official launch of commercial-stage manufacturing for its first-in-class oligotrophic recombinant adeno-associated virus gene therapy product, developed specifically for...",
    "url": "https://finnhub.io/api/news?id=581346fb446118688ed033a566eff401dd4d2b1d4f7e780c94f7ed4160cdc49b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751977231,
      "headline": "Myrtelle Inc. Launches Manufacturing of First-in-Class Gene Therapy for Canavan Disease in Strategic Alliance with Charles River and Viralgen Vector Core",
      "id": 135810028,
      "image": "",
      "related": "CRL",
      "source": "Finnhub",
      "summary": "Myrtelle Inc. announced the official launch of commercial-stage manufacturing for its first-in-class oligotrophic recombinant adeno-associated virus gene therapy product, developed specifically for...",
      "url": "https://finnhub.io/api/news?id=581346fb446118688ed033a566eff401dd4d2b1d4f7e780c94f7ed4160cdc49b"
    }
  },
  {
    "ts": null,
    "headline": "Myrtelle Launches Manufacturing of First-in-Class Gene Therapy for Canavan Disease in Strategic Alliance with Charles River and Viralgen",
    "summary": "Myrtelle Inc. (\"Myrtelle\" or the \"Company\"), a pioneering clinical-stage gene therapy company dedicated to revolutionizing treatment for neurodegenerative diseases, today announced the official launch of commercial-stage manufacturing for its first-in-class oligotrophic recombinant adeno-associated virus (rAAV) gene therapy product, developed specifically for Canavan disease (CD). This landmark achievement propels Myrtelle's therapy closer to market and patients who urgently need it.",
    "url": "https://finnhub.io/api/news?id=7cc516cb32c2adda104589d8abaa51cf3d228669f3fc51b09ba42234775dcdf3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751976660,
      "headline": "Myrtelle Launches Manufacturing of First-in-Class Gene Therapy for Canavan Disease in Strategic Alliance with Charles River and Viralgen",
      "id": 135807295,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRL",
      "source": "Yahoo",
      "summary": "Myrtelle Inc. (\"Myrtelle\" or the \"Company\"), a pioneering clinical-stage gene therapy company dedicated to revolutionizing treatment for neurodegenerative diseases, today announced the official launch of commercial-stage manufacturing for its first-in-class oligotrophic recombinant adeno-associated virus (rAAV) gene therapy product, developed specifically for Canavan disease (CD). This landmark achievement propels Myrtelle's therapy closer to market and patients who urgently need it.",
      "url": "https://finnhub.io/api/news?id=7cc516cb32c2adda104589d8abaa51cf3d228669f3fc51b09ba42234775dcdf3"
    }
  }
]